Capital is the easy part of a financing round; the right investors are not. The round that backed Respiro's next phase brought in two strategic ones, each with something to add beyond the cheque.
Sanner, the drug-delivery and medical-packaging group, invested through its corporate venture arm, Sanner Ventures, pairing decades of device and dosing experience with our sensor technology. Breed Reply, the investor specialised in connected products and the Internet of Things, brought depth in building and scaling connected devices. The funds went into expanding the Respiro platform: the sensors, the app and the data layer behind connected inhaled therapy.
"Together with Amiko's digital Respiro Platform and unique sensor technology, we will transform our synergies into smart solutions for true medication adherence in respiratory care."
Dirk Mähr, Managing Director of Sanner GmbH
The value, for us, was in who was backing the work: investors who understood both the device and the data, and could help build it rather than just fund it. The development collaboration with Sanner was presented at Pharmapack Europe in Paris soon after.
"Strategic investors who understand both the device and the data are rare. Sanner and Breed Reply backed what we were building, not just the company, and that is what let Respiro reach further."
Duilio Macchi, Amministratore Delegato, Amiko
The investment round closed in January 2018. Strategic investors: Sanner (through Sanner Ventures) and Breed Reply.